Soligenix Inc. SNGX Archives - Page 2 of 6

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed…

FridayNov 28, 2025 2:25 pm

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Heat-Stable Vaccine Platform with New Peer-Reviewed Data

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines. The company recently published a peer-reviewed summary of new scientific data demonstrating long-term high-temperature stability of its protein subunit vaccine platform designed for Ebola and Marburg-related viruses. An article discussing this reads, “Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C, a capability that could transform global outbreak response readiness. The company’s publication, titled ‘Development of Thermostable Filovirus Vaccines Using Protein Subunit Technology,’ outlines preclinical data showing that the company’s filovirus vaccine antigens, formulated with its proprietary ThermoVax(R)…

TuesdayNov 25, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Elevates Advisory Network as Rare Disease Strategy Advances

Philipson will serve as a strategic advisor to Soligenix, contributing extensive expertise in U.S. economic policy, healthcare regulation and corporate strategy. The significance of this appointment lies in the convergence of science, healthcare regulation and policy economics. The addition of Philipson complements the company’s mission to develop and commercialize products to treat rare diseases where there is an unmet medical need. Soligenix (NASDAQ: SNGX) is entering a new phase of strategic breadth and influence with the appointment of a seasoned, high-level scientific and policy adviser who brings rarefied experience at the intersection of economics, government and healthcare innovation. The company,…

MondayNov 24, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens CTCL Program as DMC Flags No Safety Issues

This milestone is significant because regulatory pathways for orphan diseases such as CTCL often hinge not only on efficacy, but on establishing a favorable safety profile. Soligenix’s announcement arrives amid mounting interest in HyBryte[TM] as a novel skin-directed therapy. For biotechnology companies working in rare diseases, reaching a safety milestone means one major hurdle is cleared and focus can shift more explicitly to efficacy and regulatory strategy. In a key development that underscores the advancing clinical trajectory of its lead therapy, Soligenix (NASDAQ: SNGX) announced that the Data Monitoring Committee (“DMC”) overseeing its confirmatory Phase 3 FLASH2 trial of HyBryte(TM)…

TuesdayNov 04, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers

The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix. The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing. SNGX has outlined a timeline of catalysts extending through the end of 2026. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash…

MondayNov 03, 2025 12:45 pm

Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte(TM) (synthetic hypericin) and related therapies. These changes are timely given the complexities of CTCL and the evolving therapeutic landscape. The company’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight. Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise…

TuesdayOct 28, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability

Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been developing formulations intended to remain stable even when stored for extended periods at temperatures above 40°C. Soligenix’s ThermoVax(R) technology has broad applicability in Emerging Infectious Disease. Current vaccines for Ebola and similar filoviruses face a major deployment barrier: Most require storage between 2°C and 8°C throughout transport, making them vulnerable to spoilage when exposed to the high ambient heat common in many outbreak regions (https://ibn.fm/MZWfk). Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in biodefense and rare disease vaccines, has published a peer-reviewed summary of…

MondayOct 13, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026

The closing of the public offering provides the company with critical financial flexibility as it continues to advance its pipeline of products. The $7.5 million raised through the public offering is particularly significant in the context of Soligenix’s ongoing clinical development programs. SNGX notes multiple potential value drivers over the next 18 months, including clinical milestones, regulatory interactions and data readouts across its pipeline. Soligenix (NASDAQ: SNGX) recently announced the closing of a $7.5 million public offering, providing the company with additional capital to advance its pipeline (https://ibn.fm/tCsub). This funding extends Soligenix’s cash runway through the end of 2026, ensuring…

ThursdayOct 09, 2025 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL

The expansion of Soligenix’s European Medical Advisory Board underscores the company's commitment to delivering innovative treatment options to European patients. HyBryte (synthetic hypericin) is a first-in-class, photodynamic therapy using synthetic hypericin as a photosensitizer. The company’s efforts could establish HyBryte as a new standard of care for patients who currently have limited options. Cutaneous T-cell lymphoma (“CTCL”) is a rare but serious form of non-Hodgkin lymphoma that primarily affects the skin. Globally, millions suffer from CTCL, and in Europe, the annual incidence is estimated at 2.9 to 3.9 cases per million people (https://ibn.fm/ANk8X). Despite its rarity, CTCL presents a substantial…

TuesdaySep 30, 2025 9:20 am

QualityStocksNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on treatments for rare diseases, announced the expansion of its European Medical Advisory Board to guide its confirmatory Phase 3 trial of HyBryte(TM) in early-stage cutaneous T-cell lymphoma, an 18-week study enrolling about 80 patients with top-line results expected in the second half of 2026, as the company strengthens European engagement ahead of potential commercialization. To view the full press release, visit https://ibn.fm/Dswzt About Soligenix Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business…

Site Search

Company Search

Tag: Soligenix Inc. SNGX